Shares of Genelux Corporation (NASDAQ:GNLX - Get Free Report) have been assigned an average rating of "Moderate Buy" from the five analysts that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $19.25.
A number of analysts recently commented on the stock. Weiss Ratings restated a "sell (e+)" rating on shares of Genelux in a research report on Wednesday, October 8th. Lake Street Capital started coverage on Genelux in a research report on Tuesday. They issued a "buy" rating and a $16.00 price objective for the company. HC Wainwright restated a "buy" rating on shares of Genelux in a report on Wednesday, July 23rd. Finally, Wall Street Zen upgraded shares of Genelux from a "sell" rating to a "hold" rating in a report on Saturday, July 12th.
Check Out Our Latest Analysis on Genelux
Genelux Price Performance
Shares of NASDAQ GNLX opened at $6.51 on Tuesday. The company's 50 day simple moving average is $4.11 and its 200 day simple moving average is $3.30. Genelux has a fifty-two week low of $1.99 and a fifty-two week high of $6.52. The firm has a market capitalization of $245.90 million, a P/E ratio of -7.57 and a beta of -0.22.
Genelux (NASDAQ:GNLX - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.02. Sell-side analysts expect that Genelux will post -0.88 EPS for the current fiscal year.
Institutional Trading of Genelux
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Woodward Diversified Capital LLC raised its position in Genelux by 21.7% during the second quarter. Woodward Diversified Capital LLC now owns 1,778,286 shares of the company's stock worth $5,104,000 after acquiring an additional 317,173 shares in the last quarter. Alyeska Investment Group L.P. bought a new position in shares of Genelux during the 1st quarter worth approximately $770,000. Flputnam Investment Management Co. raised its stake in Genelux by 708.1% in the 3rd quarter. Flputnam Investment Management Co. now owns 300,290 shares of the company's stock valued at $1,261,000 after acquiring an additional 263,131 shares during the period. Heights Capital Management Inc. acquired a new stake in Genelux during the 1st quarter valued at $644,000. Finally, MAI Capital Management boosted its position in Genelux by 66,161.3% during the second quarter. MAI Capital Management now owns 236,553 shares of the company's stock worth $679,000 after purchasing an additional 236,196 shares during the period. Institutional investors own 37.33% of the company's stock.
About Genelux
(
Get Free Report)
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Genelux, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genelux wasn't on the list.
While Genelux currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.